CB-103

DB15279InvestigationalSmall molecule

CB-103 is under investigation in clinical trial NCT03422679 (Study of CB-103 in Adult Patients With Advanced or Metastatic Solid Tumours and Haematological Malignancies).

Mechanism: Pharmacologically active on Neurogenic locus notch homolog protein 1, Neurogenic locus notch homolog protein 4, and Neurogenic locus notch homolog protein 2
Curator reviewed
Formula / weight: C₁₅H₁₈N₂O · 242.322 g/mol (avg)
Also known as: 3-PYRIDINAMINE, 6-(4-(1,1-DIMETHYLETHYL)PHENOXY)- · 6-(4-(1,1-Dimethylethyl)phenoxy)-3-pyridinamine
Code names: CB-103

Resolves to

Compound

UNIIQ5BB91JL0VCAS218457-67-1ChEMBLCHEMBL1420319

Structure

InChIKeyWHIWGRCYMQLLAO-UHFFFAOYSA-NSMILESCC(C)(C)C1=CC=C(OC2=CC=C(N)C=N2)C=C1

Targets

P46531NOTCH1Q99466NOTCH4Q04721NOTCH2Q06330RBPJQ9UM47NOTCH3

What you can answer from here — as of August 30, 2026

5Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

4Clinical trialsPhase, status and sponsor resolved per trial

15+ReferencesStructured and connected to the statements they support

Which drugs share a target with CB-103, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account